NASDAQ:OCX - OncoCyte Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.48 -0.31 (-6.47 %) (As of 05/24/2019 04:00 PM ET)Previous Close$4.48Today's Range$4.45 - $4.8952-Week Range$1.16 - $6.92Volume98,142 shsAverage Volume898,626 shsMarket Capitalization$232.84 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc. Receive OCX News and Ratings via Email Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCX Previous Symbol CUSIPN/A CIKN/A Webhttp://www.oncocyte.com/ Phone510-775-0515Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees16 Outstanding Shares51,973,000Market Cap$232.84 million Next Earnings Date8/13/2019 (Estimated) OptionableOptionable OncoCyte (NASDAQ:OCX) Frequently Asked Questions What is OncoCyte's stock symbol? OncoCyte trades on the NASDAQ under the ticker symbol "OCX." How were OncoCyte's earnings last quarter? OncoCyte Corporation (NASDAQ:OCX) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.02. View OncoCyte's Earnings History. When is OncoCyte's next earnings date? OncoCyte is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for OncoCyte. What is the consensus analysts' recommendation for OncoCyte? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte. Has OncoCyte been receiving favorable news coverage? News stories about OCX stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OncoCyte earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of OncoCyte's key competitors? Some companies that are related to OncoCyte include Mesoblast (MSB), Polynovo (PNV), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Starpharma (SPL), Biotest (BIO), Oxford BioMedica (OXB), Neptune Wellness Solutions (NEPT), Theratechnologies (TH), Senesco Technologies (ELOX), Kodiak Sciences (KOD), IMV (IMV), Monash IVF Group (MVF), Paradigm Biopharmaceuticals (PAR) and 22nd Century Group (XXII). What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Arca Biopharma (ABIO), Geron (GERN), Athersys (ATHX), Array Biopharma (ARRY), ArQule (ARQL), Digital Turbine (APPS), Achaogen (AKAO), Atlas Financial (AFH), Abeona Therapeutics (ABEO) and Sirius Minerals (SXX). Who are OncoCyte's key executives? OncoCyte's management team includes the folowing people: Mr. William Annett, Pres, CEO & Director (Age 65)Mr. Mitchell S. Levine, Chief Financial OfficerDr. Lyndal K. Hesterberg, Chief Scientific OfficerMr. Albert P. Parker II, Chief Operating OfficerDr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66) How do I buy shares of OncoCyte? Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OncoCyte's stock price today? One share of OCX stock can currently be purchased for approximately $4.48. How big of a company is OncoCyte? OncoCyte has a market capitalization of $232.84 million. OncoCyte employs 16 workers across the globe. What is OncoCyte's official website? The official website for OncoCyte is http://www.oncocyte.com/. How can I contact OncoCyte? The company can be reached via phone at 510-775-0515. MarketBeat Community Rating for OncoCyte (NASDAQ OCX)Community Ranking: 3.8 out of 5 ( )Outperform Votes: 3 (Vote Outperform)Underperform Votes: 1 (Vote Underperform)Total Votes: 4MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: How to invest in a bear market Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.